Trial Profile
A Single Centre, Single-blind, Randomized, Two-part, 6-way Cross-over Study to Investigate the Individual Bioequivalence of Gabasandoz Relative to Neurontin in Healthy Volunteers.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Apr 2022
Price :
$35
*
At a glance
- Drugs Gabapentin (Primary)
- Indications Amyotrophic lateral sclerosis; Anxiety disorders; Bipolar disorders; Epilepsy; Hot flashes; Migraine; Neuralgia; Neuropathic pain; Postherpetic neuralgia; Restless legs syndrome; Spinal muscular atrophy
- Focus Pharmacokinetics
- 13 Jan 2019 Results published in the Clinical Pharmacology and Therapeutics
- 06 Apr 2013 New trial record
- 01 Apr 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov